1. Home

Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template

NICE process and methods [PMG24] Published: 08 January 2015 Last updated: 03 December 2024

  • Process
  • Tools and resources
  • Overview
  • Instructions for companies
  • 1 Decision problem, description of the technology and clinical care pathway
  • 2 Clinical effectiveness
  • 3 Cost effectiveness
  • 4 References
  • 5 Appendices
  • Appendix A: Summary of product characteristics (SmPC) and UK public assessment report
  • Appendix B: Identification, selection and synthesis of clinical evidence
  • Appendix C: Subgroup analysis
  • Appendix D: Adverse reactions
  • Appendix E: Published cost-effectiveness studies
  • Appendix F: Health-related quality-of-life studies
  • Appendix G: Cost and healthcare resource identification, measurement and valuation
  • Appendix H: Clinical outcomes and disaggregated results from the model
  • Appendix I: Price details of treatments included in the submission
  • Update information
Download (PDF)

NICE process and methods

Update information

Update information

December 2024: A company submission summary (previously Document A) is no longer required when submitting to NICE for a medicines evaluation, so we updated the user guide to reflect this. We also clarified and added detail on the types of evidence required in different sections of the company evidence submission.

ISBN: 978-1-4731-6676-9